Journal of International Oncology››2016,Vol. 43››Issue (1): 1-4.doi:10.3760/cma.j.issn.1673-422X.2016.01.001
Shi Pengju, Zhao Gang, Cai Haifeng, Liu Huiren, Zhu Pengfei, Zhao Yanhui, Zhang Tieshan
Received:
2015-05-12Online:
2016-01-08Published:
2015-12-03Contact:
Zhao Gang E-mail:zhaog998@126.comSupported by:
Science and Technology Research and Development Program of Tangshan City of China (12150222B-8)
Shi Pengju, Zhao Gang, Cai Haifeng, Liu Huiren, Zhu Pengfei, Zhao Yanhui, Zhang Tieshan. Clinical study of onestage lymphatics-venous anastomosis to prevent upper extremity lymphedema of breast cancer after radical resection[J]. Journal of International Oncology, 2016, 43(1): 1-4.
[1] Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients[J]. Ann Surg, 2007, 245(3): 452-461. DOI:10.1097/01.sla.0000245472.47748.ec. [2] Pusic AL, Cemal Y, Albornoz C, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patientreported outcome instruments and outcomes[J/OL] . J Cancer Surviv, 2013, 7(1): 83-92. DOI:10.1007/s11764-012-0247-5. [3] 李树玲. 乳腺肿瘤学[M] . 第2版. 北京: 科学技术文献出版社, 2007: 693. [4] 孟慧敏, 谷元廷, 李林. 乳腺癌前哨淋巴结活检替代腋淋巴结清除临床应用的观察[J]. 中华肿瘤防治杂志, 2012, 20(20): 1560-1562. [5] 张秀萍, 彭伟强, 李健, 等. 早期乳腺癌前哨淋巴结活检与腋窝局部放疗决策[J]. 重庆医学, 2006, 35(2): 117-118, 121.DOI:10.3969/j.issn.1671-8348.2006.02.011. [6] Auba C, Marre D, RodríguezLosada G, et al. Lymphaticovenular anastomoses for lymphedema treatment: 18 months postoperative outcomes[J]. Microsurgery, 2012, 32(4): 261-268. DOI:10.1002/micr.20980. [7] 侍朋举, 张文龙, 赵刚, 等. 改良静脉淋巴管吻合技术治疗乳腺癌术后上肢淋巴水肿[J]. 中国修复重建外科杂志, 2015, 29(3): 339-342. DOI:10.7507/1002-1892.20150072. [8] Suami H, Chang DW. Overview of surgical treatments for breast cancerrelated lymphedema[J]. Plast Reconstr Surg, 2010, 126(6): 1853-1863. DOI:10.1097/PRS.0b013e3181f44658. [9] Campisi C, Boccardo F. Microsurgical techniques for lymphedema treatment: derivative lymphaticvenous microsurgery[J]. World J Surg, 2004, 28(6): 609-613. |
[1] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[2] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[3] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[4] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[5] | Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer: present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58. |
[6] | Wang Jing, Xu Wenting.Value of NLR, CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526. |
[7] | Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531. |
[8] | Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456. |
[9] | Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462. |
[10] | Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356. |
[11] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367. |
[12] | Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240. |
[13] | Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149. |
[14] | Li Lixi, Zhang Di, Luo Yang, Ma Fei.Clinical application of PARP inhibitors in breast cancer[J]. Journal of International Oncology, 2023, 50(2): 91-96. |
[15] | Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng.Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors[J]. Journal of International Oncology, 2023, 50(11): 650-654. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||